Gilead Sciences, Inc. (SNSE:GILD)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CLP 144.88 trillion. The enterprise value is 158.20 trillion.

Market Cap	144.88T
Enterprise Value	158.20T

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Sep 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.31%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.58 and the forward PE ratio is 15.11.

PE Ratio	18.58
Forward PE	15.11
PS Ratio	5.18
PB Ratio	7.02
P/TBV Ratio	n/a
P/FCF Ratio	16.44
P/OCF Ratio	15.58
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.92, with an EV/FCF ratio of 17.96.

EV / Earnings	20.29
EV / Sales	5.86
EV / EBITDA	11.92
EV / EBIT	14.99
EV / FCF	17.96

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 16.14%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	16.14%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	1.59B
Profits Per Employee	443.11M
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 1.71 trillion in taxes.

Income Tax	1.71T
Effective Tax Rate	17.96%

Stock Price Statistics

The stock price has increased by +23.10% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+23.10%
50-Day Moving Average	110.43
200-Day Moving Average	101.52
Relative Strength Index (RSI)	100.00
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.33

Income Statement

In the last 12 months, Gilead Sciences had revenue of CLP 27.97 trillion and earned 7.80 trillion in profits. Earnings per share was 6,176.27.

Revenue	27.97T
Gross Profit	22.02T
Operating Income	10.93T
Pretax Income	9.51T
Net Income	7.80T
EBITDA	13.59T
EBIT	10.93T
Earnings Per Share (EPS)	6,176.27

Balance Sheet

The company has 8.16 trillion in cash and 23.98 trillion in debt, giving a net cash position of -13,891.42 billion.

Cash & Cash Equivalents	8.16T
Total Debt	23.98T
Net Cash	-13,891.42B
Net Cash Per Share	n/a
Equity (Book Value)	20.63T
Book Value Per Share	16,677.20
Working Capital	5.36T

Cash Flow

In the last 12 months, operating cash flow was 9.30 trillion and capital expenditures -485.61 billion, giving a free cash flow of 8.81 trillion.

Operating Cash Flow	9.30T
Capital Expenditures	-485.61B
Free Cash Flow	8.81T
FCF Per Share	n/a

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

This stock pays an annual dividend of 2,987.15, which amounts to a dividend yield of 2,705.02%.

Dividend Per Share	2,987.15
Dividend Yield	2,705.02%
Dividend Growth (YoY)	6.59%
Years of Dividend Growth	1
Payout Ratio	49.10%
Buyback Yield	-1.02%
Shareholder Yield	2,704.00%
Earnings Yield	5.38%
FCF Yield	6.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7